Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China · Delayed Price · Currency is CNY 30.05
+0.65 (2.21%)
Aug 21, 2026, 3:00 PM CST
SHA:688319 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 232.68 | 246.61 | 224.16 | 362.07 | 269.23 | 254.37 |
Trading Asset Securities | 2.6 | 2.6 | 17.5 | 0 | 90 | 200 |
Cash & Short-Term Investments | 235.28 | 249.21 | 241.66 | 362.07 | 359.23 | 454.37 |
Cash Growth | 16.52% | 3.12% | -33.26% | 0.79% | -20.94% | 298.63% |
Accounts Receivable | 747.37 | 655.97 | 570.35 | 491.55 | 491.69 | 342.52 |
Other Receivables | 1.74 | 2.58 | 1 | 1.1 | 3.78 | 1.1 |
Receivables | 749.11 | 658.55 | 571.35 | 492.65 | 495.48 | 343.62 |
Inventory | 60.59 | 62.38 | 85.68 | 72.12 | 78.52 | 74.5 |
Prepaid Expenses | - | 1.05 | - | 0 | 0 | 0.06 |
Other Current Assets | 30.3 | 25.14 | 9.45 | 4.35 | 2.66 | 2.42 |
Total Current Assets | 1,075 | 996.33 | 908.14 | 931.19 | 935.89 | 874.98 |
Property, Plant & Equipment | 620.53 | 630.67 | 572.3 | 425.87 | 378.35 | 259.27 |
Other Intangible Assets | 16.53 | 16.9 | 16.33 | 16.82 | 17.51 | 13.78 |
Long-Term Deferred Tax Assets | 29 | 24.91 | 18.21 | 14.07 | 9.56 | 7.11 |
Long-Term Deferred Charges | 358.01 | 354.04 | 291.5 | 195.76 | 132.31 | 34.93 |
Other Long-Term Assets | 0.36 | 0.22 | 0.56 | 28.89 | 5.24 | 21.82 |
Total Assets | 2,100 | 2,023 | 1,807 | 1,613 | 1,479 | 1,212 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 145.61 | 153.07 | 86.29 | 40.06 | 80.68 | 34.28 |
Accrued Expenses | 1.77 | 465.14 | 368.06 | 346.13 | 321.65 | 251.98 |
Short-Term Debt | 50 | 30 | 24.2 | 24.2 | 85 | 35 |
Current Portion of Long-Term Debt | 151.79 | 68.82 | 87.42 | 31.69 | 10 | - |
Current Portion of Leases | - | 3.24 | - | - | - | - |
Current Income Taxes Payable | 15.72 | - | 9.44 | 3.74 | 9.46 | 4.03 |
Current Unearned Revenue | 3.91 | 0.99 | 0.51 | 3.62 | 6.71 | 7.5 |
Other Current Liabilities | 467.49 | 15.83 | 19.67 | 26.79 | 11.73 | 8.88 |
Total Current Liabilities | 836.29 | 737.07 | 595.59 | 476.22 | 525.23 | 341.66 |
Long-Term Debt | 317.55 | 323.72 | 249.53 | 177.29 | 29.99 | - |
Long-Term Leases | 4.77 | 7.26 | 0.64 | 4.43 | 9.04 | 3.25 |
Long-Term Unearned Revenue | 43.39 | 29.16 | 24.79 | 19.98 | 20.11 | 18.67 |
Long-Term Deferred Tax Liabilities | 10.56 | 8.39 | 2.46 | 2.72 | 2.56 | 2.3 |
Other Long-Term Liabilities | 17.83 | 13.48 | 0.53 | 1.21 | 0.09 | 1.33 |
Total Liabilities | 1,230 | 1,119 | 873.54 | 681.84 | 587.02 | 367.22 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 405.41 | 405.71 | 405.93 | 406.16 | 405.27 | 405.27 |
Additional Paid-In Capital | 556.21 | 560.58 | 606 | 605.75 | 580.95 | 570.56 |
Retained Earnings | -92.3 | -59.44 | -81.7 | -87.04 | -104.59 | -131.17 |
Treasury Stock | - | -3.17 | -5.56 | -7.96 | - | - |
Total Common Equity | 869.33 | 903.68 | 924.68 | 916.91 | 881.63 | 844.66 |
Minority Interest | - | 0.3 | 8.82 | 13.86 | 10.22 | - |
Shareholders' Equity | 869.33 | 903.98 | 933.5 | 930.77 | 891.85 | 844.66 |
Total Liabilities & Equity | 2,100 | 2,023 | 1,807 | 1,613 | 1,479 | 1,212 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 524.1 | 433.03 | 361.79 | 237.61 | 134.03 | 38.25 |
Net Cash (Debt) | -288.83 | -183.82 | -120.13 | 124.47 | 225.2 | 416.11 |
Net Cash Growth | - | - | - | -44.73% | -45.88% | 381.08% |
Net Cash Per Share | -0.71 | -0.45 | -0.30 | 0.31 | 0.56 | 1.08 |
Filing Date Shares Outstanding | 405.46 | 405.71 | 405.93 | 406.16 | 405.27 | 405.27 |
Total Common Shares Outstanding | 405.46 | 405.71 | 405.93 | 406.16 | 405.27 | 405.27 |
Working Capital | 239 | 259.26 | 312.55 | 454.97 | 410.67 | 533.31 |
Book Value Per Share | 2.14 | 2.23 | 2.28 | 2.26 | 2.18 | 2.08 |
Tangible Book Value | 852.8 | 886.78 | 908.35 | 900.08 | 864.11 | 830.88 |
Tangible Book Value Per Share | 2.10 | 2.19 | 2.24 | 2.22 | 2.13 | 2.05 |
Buildings | - | 224.69 | 224.69 | 96.22 | 103.17 | 103.17 |
Machinery | - | 383.4 | 318.26 | 299.39 | 261.88 | 245.29 |
Construction In Progress | - | 226.26 | 211.27 | 181.35 | 135.49 | 11.63 |